Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.35 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29420806 | 1.00 | EGFR (0.42) | EGFREPHX2FLT3KCNH2SCN9A | |
| SCHEMBL22931770 | 0.91 | FLT3 (0.41) | EGFREPHX2FLT3KCNH2SCN9A | |
| SCHEMBL29420796 | 0.87 | DHODH (0.40) | EGFREPHX2FLT3DHODH | |
| SCHEMBL22932203 | 0.87 | DHODH (0.40) | EGFREPHX2FLT3DHODH | |
| SCHEMBL29420795 | 0.84 | EPHX2 (0.37) | EGFREPHX2FLT3DHODH | |
| SCHEMBL22932193 | 0.84 | EPHX2 (0.37) | EGFREPHX2FLT3DHODH | |
| SCHEMBL22931766 | 0.83 | EPHX2 (0.45) | EPHX2FLT3DHODH | |
| SCHEMBL24755062 | 0.80 | DHODH (0.40) | EGFREPHX2FLT3DHODH | |
| SCHEMBL22931802 | 0.80 | EPHX2 (0.45) | EPHX2 | |
| SCHEMBL29420799 | 0.80 | EPHX2 (0.45) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402900-A1 | 1,2,4-OXADIAZOL-5-ONE DERIVATIVES FOR THE TREATMENT OF CANCER | BASILEA PHARM INT AG (CH) | 2022-12-22 | — | — | US | disclosed |
| WO-2021018869-A1 | 1,2,4-OXADIAZOL-5-ONE DERIVATIVES FOR THE TREATMENT OF CANCER | Basilea Pharmaceutica International AG (CH) | 2021-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402900-A1 | 1,2,4-OXADIAZOL-5-ONE DERIVATIVES FOR THE TREATMENT OF CANCER | OXER1, CBR3, CCNY | EGFR 355/4885EPHX2 755/4885FLT3 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.